Kelun hands dual chairmanship to Liu Sichuan as antibiotic profit drops 46% and sac-TMT scales
Sichuan Kelun Pharmaceutical (SZSE: 002422, Notice 2026-087) and Kelun-Biotech (HKEX: 06990) elected Liu Sichuan chairman on Nov 18, 2026 as Chuanning Biotech 9M profit fell 45.6% and sac-TMT scaled.
Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE: 002422, Announcements No. 2026-086 and 2026-087) and its majority-owned oncology biotechnology subsidiary Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKEX: 06990) simultaneously announced on November 18–19, 2026 that 75-year-old founder Liu Gexin has stepped down as chairman of both boards, handing the dual chairmanship to his 42-year-old son Liu Sichuan. While Liu Sichuan now serves concurrently as chairman, legal representative, and general manager of parent Kelun Pharmaceutical as well as non-executive chairman and nomination-committee chair of Kelun-Biotech—and Liu Gexin retains his director seats and chairs the parent board’s Strategy Committee—the generational handover coincides with a sharp financial divergence across the group’s three listed entities: antibiotic-intermediate subsidiary Yili Chuanning Biotechnology Co., Ltd. (SZSE: 301301, Announcement No. 2026-034) saw nine-month 2026 net profit plunge 45.63% year-on-year to RMB 332.43 million (approx. $46.0 million), whereas parent Kelun Pharmaceutical’s Q3 2026 recurring net profit (Koufei) (Announcement No. 2026-083) jumped 124.06% to RMB 361.80 million (approx. $50.0 million) on the back of Kelun-Biotech’s licensing revenue recognition and commercial ramp-up of its TROP2 antibody-drug conjugate sacituzumab tirumotecan (sac-TMT / MK-2870 / SKB264, marketed in China as Jiatailai).
How the November 18 board reshuffle divides operational control and capital-allocation authority
Founded by Liu Gexin in 1996 from a restructured Sichuan infusion plant, the Kelun Group operates a three-pillar listed structure: parent Kelun Pharmaceutical (002422.SZ, intravenous infusions and generics), Chuanning Biotech (301301.SZ, fermentation-derived antibiotic intermediates and synthetic biology, spun off onto ChiNext in December 2022), and Kelun-Biotech (06990.HK, ADCs and novel biologics, listed under Hong Kong’s Chapter 18A in July 2023 and tracked in our Windward Bio respiratory NewCo report).
Cross-checking the November 18–19 governance filings across Shenzhen and Hong Kong clarifies how control is partitioned after the handover:
- Parent Kelun Pharmaceutical (
SZSE: 002422, Announcements2026-086&2026-087): By a9-0-0vote of the Eighth Board of Directors on November 18, 2026, Liu Sichuan (born 1984; general manager since September 2015 and director since June 2009) was elected chairman and legal representative while continuing as general manager. Liu Sichuan holds8,346,286shares (0.52%) directly and22,650,600shares indirectly via three Tongyi Wutong private securities investment funds (30,996,886shares combined, or ~1.95%). Founder Liu Gexin remains the company’s largest shareholder with379,128,280shares (23.83%, of which84,630,000shares or22.3%were pledged as of September 30, 2026) and stays on the board as Chairman of the Strategy Committee and a director of key subsidiaries. - Subsidiary Kelun-Biotech (
HKEX: 06990, November 18 filing): Liu Sichuan was elected Chairman of the Board and Chairman of the Nomination Committee (stepping down from the Remuneration Committee), while Liu Gexin remains a non-executive director and joins the Remuneration Committee. Under his June 20, 2025 non-executive director service contract, Liu Sichuan receives zero director’s fees and zero additional remuneration from Kelun-Biotech for serving as chairman, while CEO and Executive Director Dr. Ge Junyou continues to lead day-to-day R&D and commercial execution.
What the Q3 2026 statutory income statements reveal: antibiotic-intermediate contraction versus sac-TMT and settlement windfalls
The timing of the succession—matched on November 18 by Kelun-Biotech holding its 2026 national distributor conference in Shanghai rather than Chengdu—reflects a fundamental shift in where the group’s earnings and cash flow originate. Auditing the Q3 2026 reports of Kelun Pharmaceutical (2026-083) and Chuanning Biotech (2026-034, where Kelun Pharmaceutical holds 72.12% combined equity) shows three distinct earnings drivers:
| Entity & Statutory Line Item (PRC GAAP) | Q3 2026 (Jul–Sep) | YoY Change | 9M 2026 (Jan–Sep) | YoY Change / Filing Note |
|---|---|---|---|---|
Kelun Pharmaceutical (002422.SZ, Consolidated) — Operating revenue |
RMB 4,274.22M (approx. $591.2M) | +1.93% | RMB 13,112.75M (approx. $1.81B) | -1.24% |
| Kelun Pharmaceutical — Net profit attributable to shareholders | RMB 339.26M (approx. $46.9M) | +69.60% | RMB 1,467.03M (approx. $202.9M) | +22.18% |
Kelun Pharmaceutical — Recurring net profit (Koufei) |
RMB 361.80M (approx. $50.0M) | +124.06% | RMB 1,061.17M (approx. $146.8M) | -7.48% |
Kelun Pharmaceutical — Non-operating income (Yingyewai Shouru) |
— | — | RMB 711.09M (approx. $98.4M) | +15,223.71% vs. RMB 4.64M in 9M 2025 (“receipt of settlement payment”) |
Kelun Pharmaceutical — Contract liabilities (Hetong Fuzhai) |
— | — | RMB 247.45M (approx. $34.2M) | -44.79% vs. RMB 448.18M at year-end 2025 (“recognition of licensing revenue”) |
Kelun Pharmaceutical — Minority interest profit (Shaoshu Gudong Sunyi) |
— | — | RMB 307.61M (approx. $42.5M) | +597.45% vs. RMB 44.10M in 9M 2025 (“profit increase at non-wholly-owned subsidiaries”) |
Chuanning Biotech (301301.SZ) — Operating revenue |
RMB 785.08M (approx. $108.6M) | -27.80% | RMB 2,882.80M (approx. $398.7M) | -16.10% |
| Chuanning Biotech — Net profit attributable to shareholders | RMB 54.92M (approx. $7.6M) | -64.91% | RMB 332.43M (approx. $46.0M) | -45.63% |
| Chuanning Biotech — R&D expenses | — | — | RMB 56.42M (approx. $7.8M) | -32.55% (“reduction in synthetic-biology product R&D spend”) |
Three accounting lines in Kelun Pharmaceutical’s Q3 report (2026-083) explain the earnings bridge that Liu Sichuan now inherits:
- Chuanning Biotech’s cyclical downturn and synthetic-biology R&D pullback: Over the first nine months of 2026, Chuanning Biotech’s revenue fell 16.10% to RMB 2.88 billion and Q3 single-quarter net profit dropped 64.91% to RMB 54.92 million, prompting management to trim synthetic-biology R&D spending by 32.55% YoY to RMB 56.42 million while rolling over RMB 200 million in 270-day ultra-short-term commercial paper at a 1.52% coupon in October 2026 (
Announcement No. 2026-033). - A RMB 711.09 million non-operating settlement windfall boosted headline 9M net profit: While Kelun Pharmaceutical’s headline 9M 2026 net profit rose 22.18% to RMB 1.47 billion, underlying 9M recurring net profit actually declined 7.48% to RMB 1.06 billion. The gap was bridged by RMB 405.86 million in net non-recurring gains, anchored by RMB 711.09 million in non-operating income from a legal settlement payment received during the period (partially offset by RMB 346.11 million attributable to minority shareholders and taxes).
- Kelun-Biotech’s
sac-TMTcommercial and MSD milestone engine drove the Q3 operational inflection: In Q3 2026 alone, Kelun Pharmaceutical’s recurring net profit surged 124.06% YoY to RMB 361.80 million, while contract liabilities on the consolidated balance sheet fell 44.79% (by RMB 200.73 million) as upfront and milestone payments under licensing agreements were recognized as revenue, and minority-interest profit jumped nearly sevenfold (+597.45%) to RMB 307.61 million.
The sac-TMT (MK-2870) clinical and regulatory scorecard across China and Merck & Co.’s 15+ global Phase 3 trials
With traditional intravenous infusions capped by regional Volume-Based Procurement (VBP) and Chuanning’s fermentation margins normalizing, Kelun Group’s valuation rests on sacituzumab tirumotecan (sac-TMT), which integrates an irreversible pyrimidine-sulfone antibody conjugation linker (KthLink) with a novel belotecan-derived topoisomerase I payload (KL610023).
In China, sac-TMT (Jiatailai) is completing its first full commercial year under the National Reimbursement Drug List (NRDL) across late-line triple-negative breast cancer (TNBC, OptiTROP-Breast01) and EGFR-mutant non-small cell lung cancer (NSCLC, OptiTROP-Lung03 / OptiTROP-Lung04), with a sixth China NDA—covering first-line recurrent or metastatic TNBC with PD-L1 CPS < 10—accepted by the NMPA in July 2026, and Phase 3 first-line PD-L1-negative non-squamous NSCLC data (OptiTROP-Lung06, sac-TMT + pembrolizumab vs. chemotherapy + pembrolizumab, LBA66) published in The New England Journal of Medicine (doi:10.1056/NEJMoa2611280) in late 2026.
Outside Greater China, partner Merck & Co. (NYSE: MRK, known as MSD ex-U.S./Canada) has advanced MK-2870 (sac-TMT) into more than 15 global Phase 3 trials—achieving positive dual primary endpoints (OS and PFS) in May 2026 in second-line advanced endometrial cancer (TroFuse-005 / ENGOT-en23 / GOG-3095, LBA11) to support sac-TMT’s first U.S. Biologics License Application (BLA), while actively recruiting large global Phase 3 cohorts across post-neoadjuvant TNBC (MK-2870-012, NCT06393374, n = 1, 530), first-line TNBC (TroFuse-011, NCT06841354, n = 1, 000), platinum-sensitive ovarian maintenance (TroFuse-022, NCT06824467, n = 770), mismatch-repair-proficient endometrial cancer (TroFuse-033, NCT06952504, n = 1, 123), and cervical cancer maintenance (TroFuse-036, NCT07216703, n = 1, 023).
Three milestones will test Liu Sichuan’s dual chairmanship over the next 12 months: whether Kelun-Biotech turns full-year GAAP operating profit positive in FY2026 on domestic NRDL hospital volume for sac-TMT without relying on one-off settlement income at the parent level; U.S. FDA acceptance and review of Merck’s initial BLA for MK-2870 (sac-TMT) following the TroFuse-005 and OptiTROP-Lung04/Lung06 readouts; and whether parent Kelun Pharmaceutical’s RMB 1.16 billion in current maturing medium-term notes ( up 446.47% as of September 30, 2026) and Chuanning Biotech’s synthetic-biology pipeline stabilize group cash flow in 2027.